Taussig J, Junge B, Burris S, Jones TS, Sterk CE. 2002. Individual and structural influences shaping pharmacists’ decisions to sell syringes to injection drug users in Atlanta, Georgia. Journal of the American Pharmaceutical Association. 42(6 Suppl 2):S40–S45.

Taylor A, Goldberg D, Hutchinson S, Cameron S, Gore SM, McMenamin J, Green S, Pithie A, Fox R. 2000. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: Are current harm reduction strategies working? Journal of Infectious Diseases. 40(2):176–183.

Thorpe L, Ouellet L, Hershow R, Bailey S, Williams I, Williamson J, Monterroso E, Garfein R. 2002. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology. 155(7):645–653.

Titus S, Marmor M, Des Jarlais D, Kim M, Wolfe H, Beatrice S. 1994. Bleach use and HIV seroconversion among New York City injection drug users. Journal of Acquired Immune Deficiency Syndromes. 7(7):700–704.

Tyndall M, Kerr T, Zhang R, King E, Montaner J, Wood E. 2006. Attendance, drug use patterns, and referrals made from North America’s first supervised injection facility. Drug and Alcohol Dependence. 83(2):193–198.

UN Nepal Information Platform. 2005. HIV/AIDS Epidemiological Situation. [Online]. Available: http://www.un.org.np/hivaids.php#nat [accessed June 23, 2006].

van Ameijden EJ, Coutinho RA. 1998. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS. 12(6):625–633.

van Ameijden EJ, Coutinho RA. 2001. Large decline in injecting drug use in Amsterdam, 1986-1998: Explanatory mechanisms and determinants of injecting transitions. Journal of Epidemiology and Community Health. 55(5):356–363.

van Ameijden EJ, van den Hoek JA, van Haastrecht HJ, Coutinho RA. 1992. The harm reduction approach and risk factors for human immunodeficiency virus (HIV) sero-conversion in injecting drug users, Amsterdam. American Journal of Epidemiology. 136(2):236–243.

van Ameijden EJ, van den Hoek AR, Coutinho RA. 1994. Injecting risk behavior among drug users in Amsterdam, 1986 to 1992, and its relationship to AIDS prevention programs. American Journal of Public Health. 84(2):275–281.

Van Bueren J, Simpson RA, Salman H, Farrelly HD, Cookson BD. 1995. Inactivation of HIV-1 by chemical disinfectants: Sodium hypochlorite. Epidemiology and Infection. 115: 567–579.

van den Hoek JA, van Haastrecht HJ, Coutinho RA. 1989. Risk reduction among intravenous drug users in Amsterdam under the influence of AIDS. American Journal of Public Health. 79(10):1355–1357.

Vazirian M, Nassirimanesh B, Zamani S, Ono-Kihara M, Kihara M, Ravari SM, Gouya MM. 2005. Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: A cross-sectional study. Harm Reduction Journal. 2:19.

Vertefeuille J, Marx MA, Tun W, Huettner S, Strathdee SA, Vlahov D. 2000. Decline in self-reported high-risk injection-related behaviors among HIV-seropositive participants in the Baltimore needle exchange program. AIDS and Behavior. 4(4):381–388.

Vickerman P, Hickman M, Rhodes T, Watts C. 2006. Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. Journal of Acquired Immune Deficiency Syndromes. 42(3):355–361.

Vlahov D. 2000. The role of epidemiology in needle exchange programs comment on A R Moss. American Journal of Public Health. 90(9):1390–1392.

Vlahov D, Munoz A, Celentano DD, Cohn S, Anthony JC, Chilcoat H, Nelson KE. 1991. HIV seroconversion and disinfection of injection equipment among intravenous drug users, Baltimore, Maryland. Epidemiology. 2(6):444–446.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement